B细胞特异性激活蛋白Pax-5在淋巴瘤组织中的表达  

Expression of B cell-specific activator protein in lymphomas

作　　者：李丹[1] 李甘地[1] 刘卫平[1] 李俸媛[1] 张文燕[1] 廖殿英[1] 

机构地区：[1]四川大学华西医院病理科

出　　处：《中华病理学杂志》2005年第6期345-347,共3页Chinese Journal of Pathology

基　　金：美国中华医学基金会(CMB)基金资助项目(00722)

摘　　要：目的探讨B细胞特异性激活蛋白(BSAP)/Pax-5在淋巴瘤的表达情况及应用价值。方法按2001年WHO关于淋巴造血组织肿瘤分类标准收集102例弥漫性大B细胞淋巴瘤(DLBCL)、3例滤泡型淋巴瘤(FL)、3例黏膜相关淋巴组织结外边缘区B细胞淋巴瘤(MALT淋巴瘤)、1例结节性淋巴细胞为主型的霍奇金淋巴瘤(NLPHL)、10例间变性大细胞淋巴瘤(ALCL)和10例浆细胞瘤,用免疫组织化学LSAB法同步检测比较BSAP与CD20的表达情况。结果102例DLBCL全部表达CD20,100例表达BSAP,3例FL、3例MALT淋巴瘤和1例NLPHLBSAP和CD20全部阳性表达,10例ALCL、10例浆细胞瘤BSAP和CD20全部阴性表达。BSAP与CD20的表达差异无统计学意义。结论BSAP/Pax-5是一种新的B细胞标记,阳性信号定位于细胞核,抗BSAP抗体在常规外科病理诊断工作中的应用价值有限。Objective To investigate the expression of B cell-specific activator protein (BSAP)/Pax-5 in lymphomas. Methods One hundred and two cases of diffuse large B-cell lymphoma (DLBCL), 3 cases of follicular lymphoma (FL), 3 cases of extranodal marginal zone B-cell lymphoma, 1 case of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), 10 cases of anaplastic large cell lymphoma (ALCL) and 10 cases of plasmacytoma were studied immunohistochemically for BSAP and CD20. Results(The tumor) cells in the 102 cases of DLBCL all expressed CD20, amongst which 100 cases also expressed BSAP. Three cases of FL, 3 cases of extranodal marginal zone B-cell lymphoma and 1 case of NLPHL also expressed BSAP and CD20. All the ALCLs and plasmacytomas did not express BSAP and CD20. The expression rates of CD20 and BSAP were highly consistent. The intensity of staining showed no statistical significance. Conclusions BSAP/Pax-5 is a novel B-cell marker expressed in tumor nuclei of B-cell lymphomas. Though less sensitive than CD20, anti-BSAP has diagnostic value in routine surgical pathology practice.

关 键 词：B细胞特异性激活蛋白 PAX-5 黏膜相关淋巴组织结外边缘区B细胞淋巴瘤 免疫组织化学LSAB法 弥漫性大B细胞淋巴瘤 MALT淋巴瘤 瘤组织 间变性大细胞淋巴瘤 淋巴细胞为主型 BSAP CD20 造血组织肿瘤 滤泡型淋巴瘤 霍奇金淋巴瘤 

分 类 号：R733.1[医药卫生—肿瘤] R392.12[医药卫生—临床医学]